Abstract: A nerve stimulation system including at least one nerve interface device is disclosed. The device includes a cuff portion having an assembled position in which the cuff portion forms at least part of a passageway for receiving a nerve along a longitudinal axis passing through the passageway; and first and second rings of electrodes mounted on the cuff portion, each ring of electrodes including a plurality of electrodes, and wherein each electrode in the first ring has a corresponding longitudinally-aligned electrode in the second ring so as to form a plurality of pairs of electrodes spaced apart from each other along the longitudinal axis. The system includes a stimulation device in communication with the pairs of electrodes to generate different electrical signals for the pairs of electrodes and a control system that causes the different signals to causes different physiological responses.

Abstract: The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.

Abstract: There is described a chimeric antigen receptor (CAR) which comprises an antigen binding domain which selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), and its use. Also described is a T cell comprising the CAR and its use in the treatment of cancer.

Abstract: A method and apparatus are provided for measuring a sensitivity level across a visual field of a subject defined by a set of locations.

Abstract: A whispering gallery mode inertial sensor includes a whispering gallery mode resonator; an evanescent coupler configured to couple with an evanescent field of the resonator so that light is transmitted to and received from the resonator by the coupler; a displacement sensor configured to determine a displacement of the resonator according to the light received from the resonator by the coupler; a controller configured to determine an acceleration and/or rate of rotations experienced by the resonator based on the displacement of the resonator, the controller being further configured to apply a restoring force to the resonator in a closed feedback loop based on the displacement of the resonator in order to maintain a predetermined mechanical state of the resonator; and a timing sensor configured to determine a timing signal based on an optical frequency comb produced by the resonator.

Abstract: The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising: (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment.

Abstract: A method for synthesising metal oxide nanoparticles. The method comprises mixing, to provide a reaction mixture, a precursor solution comprising metal ions with an initiator solution to initiate a nanoparticle precipitation process, and then quenching the precipitation process by adding a quenching agent to the reaction mixture so as to yield a dispersion comprising metal oxide nanoparticles. The resulting metal oxide nanoparticles may have an average diameter of less than 7 nm, for example 5 nm or less.

Abstract: The present invention relates to the prevention and/or treatment of retinal disorders, such as cone dystrophies, cone-rod dystrophies, in particular Achromatopsia.

Abstract: The disclosure concerns a magnetometer for detecting a magnetic field, comprising: a solid state electronic spin system containing a plurality of electronic spins and a solid carrier, wherein the electronic spins are configured to be capable of aligning with an external magnetic field in response to an alignment stimulus; and a detector configured to detect an alignment response of the electronic spins, such that the external magnetic field can be detected; wherein the electronic spins are provided as one or more groups, each group containing a plurality of spins, the plurality of spins in each of the one or more groups being arranged in a line that is angled at an angle ? with respect to the local direction of the external magnetic field at the said group. Also disclosed is a method for detecting a magnetic field.

Abstract: Provided herein is a probe for ultrasound imaging of tissue. The probe comprises an optical relay having an optically absorbing coating at the distal end of the probe for generating ultrasound from excitation light via the photoacoustic effect, wherein the generated ultrasound propagates as an ultrasound beam into the tissue; and an ultrasound receiver separate from the optical relay. The optical relay is configured to receive as input a time-varying spatial pattern of excitation light at the proximal end of the probe and to transmit the excitation light to the distal end of the probe to illuminate the optically absorbing coating in accordance with said time-varying spatial pattern, thereby generating ultrasound from the excitation light via the photoacoustic effect to propagate as a scanning ultrasound beam into the tissue. The ultrasound receiver is configured to receive reflections of the ultrasound from tissue. Such an ultrasound probe may be incorporated, for example, into a transseptal puncture needle.

Abstract: TCR The present invention relates to an engineered T cell receptor (TCR). In particular, the present invention relates to methods for expression of a TCR when expressed as an exogenous TCR, to methods for selecting a TCR with high cell surface expression when expressed as an exogenous TCR and to methods for identifying residues which contribute to the cell surface expression level of a TCR. The present invention also relates to an engineered TCR which has a high level of cell surface expression when expressed as an exogenous TCR compared to the corresponding germline TCR sequence.

Abstract: A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)

Abstract: A membrane-spanning nanopore is provided that comprises: i. at least one scaffold polynucleotide strand; ii. a plurality of staple polynucleotide strands; and iii. at least one hydrophobically-modified polynucleotide strand, wherein the at least one hydrophobically-modified polynucleotide strand comprises a polynucleotide strand and a hydrophobic moiety; wherein each of the plurality of staple polynucleotide strands hybridises to the at least one scaffold polynucleotide strand to form the three-dimensional structure of the membrane-spanning nanopore, and wherein the at least one hydrophobically-modified polynucleotide strand hybridises to a portion of the at least one scaffold polynucleotide strand, the membrane-spanning nanopore defining a central channel with a minimum internal width of at least about 5 nm.

Abstract: An end-effector for an endoscopic surgical instrument, the end-effector comprising: a tool configured to interact with tissue; a main body comprising a bearing stud, the tool being connected to the bearing stud; a base comprising a surface facing the bearing stud, the bearing stud and the surface forming a ball joint; and a plurality of tendons connected to the main body so as to control movement of the tool in two degrees of freedom.

Abstract: The invention relates to a nanofibrous material comprising a drug for treating a peripheral nerve injury by delivering the drug locally to a damaged or injured nerve. The drug may be such a Non Steroidal Anti Inflammatory Drug or a PPAR agonist. In particular, the invention relates to a drug eluting nerve wrap or bandage that can be wrapped around an injured peripheral nerve. The invention also relates to a nanofibrous drug delivery system or device for delivering a drug locally to a peripheral nerve, a treatment for a peripheral nerve injury comprising contacting a damaged nerve with the drug eluting nanofibrous material or drug delivery system, kits and methods for making the nanofibrous materials, and uses of the nanofibrous materials.

Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.

Abstract: As described below, the present invention features genetically modified immune cells having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft versus host reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.

Abstract: The present invention relates to naphthalene diimides, NDIs, and methods of synthesising them. The NDIs have DNA-quadruplex binding and stabilising activity, and potential in treatment of pancreatic, prostate, and other human cancers. The NDIs are a compound of Formula I.

Abstract: A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood.

Abstract: The invention concerns novel methods and materials for preparing extracellular matrix (ECM) powder pre-gel and gel solutions, for example for use in organoid culture. The ECM gels demonstrate excellent physiological and mechanical properties while having the proteomic signature of endoderm tissue with specific enrichment of key ECM proteins relevant to organoid formation.